Jeffrey Stein, Cidara CEO

San Diego an­ti­fun­gal play­er nabs pri­or­i­ty re­view for blood­stream in­fec­tion treat­ment

Cidara Ther­a­peu­tics wants to make its mark in the world of an­ti­fun­gals, and thanks to the FDA, it may get there soon.

The San Diego-based com­pa­ny an­nounced Tues­day that the FDA has giv­en pri­or­i­ty re­view to its an­ti­fun­gal reza­fun­gin for the treat­ment of can­didemia and in­va­sive can­didi­a­sis — com­mon caus­es of se­ri­ous blood­stream in­fec­tions in hos­pi­tal­ized pa­tients, per the CDC. No new ther­a­pies have been ap­proved in over a decade for the two in­fec­tions, the com­pa­ny said in a press state­ment. Reza­fun­gin’s re­view dead­line date is set for March 22, 2023.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.